GlassScriptPhysician profile
Somal S Shah
NPI 1295946168
$10,045.18
in general payments reported to CMS, 2019-2025
46 companies · $1,954 in 2025
The $1,954 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $934 · 2021: $1,677 · 2022: $1,345 · 2023: $1,342 · 2024: $1,444 · 2025: $1,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,739.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,642.80 | 2019-2025 | Rinvoq, Creon, Linzess |
| Janssen Biotech, INC. | $1,039.58 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $819.25 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $804.88 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $597.52 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ironwood Pharmaceuticals, INC | $420.31 | 2019-2024 | Linzess |
| Ardelyx, INC. | $380.19 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $347.46 | 2019-2022 | |
| Genzyme Corporation | $333.04 | 2022-2025 | |
| Lilly USA, LLC | $329.30 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $325.05 | 2020-2025 | Ocaliva |
| Redhill Biopharma INC. | $316.81 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $266.16 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $171.43 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $159.49 | 2023-2025 | Dupixent |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $144.87 | 2019-2023 | Rebyota |
| Gilead Sciences, INC. | $138.84 | 2019-2023 | |
| Laborie Medical Technologies Corp. | $136.50 | 2022 | |
| Virtual Incision Corporation | $120.00 | 2024 | Mira |
| Braintree Laboratories, INC. | $119.37 | 2019-2025 | Sutab, Suflave |
| Pfizer INC. | $115.51 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $108.82 | 2019 | |
| Novo Nordisk INC | $102.88 | 2020-2025 | Wegovy |
| Vivus LLC | $101.60 | 2024-2025 | Pancreaze |
| Merck Sharp & Dohme LLC | $89.38 | 2021-2023 | Dificid |
| Daiichi Sankyo INC. | $79.90 | 2019-2020 | |
| Medtronic USA, INC. | $77.30 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $75.04 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $73.51 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $65.81 | 2023 | Zeposia |
| Pharmacosmos Therapeutics INC. | $61.51 | 2023-2025 | Monoferric |
| Amgen INC. | $54.99 | 2020-2021 | |
| Madrigal Pharmaceuticals | $54.23 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $50.42 | 2023-2025 | Gimoti |
| Celgene Corporation | $47.46 | 2021-2022 | |
| Allergan, INC. | $41.65 | 2019-2020 | |
| Pentax of America, INC. | $34.66 | 2021 | |
| Kerecis Limited | $29.86 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Alnylam Pharmaceuticals INC. | $25.18 | 2024 | Givlaari |
| Shionogi INC | $24.45 | 2020 | |
| Shire North American Group INC | $24.28 | 2019 | |
| Ethicon US, LLC | $20.98 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.75 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $18.90 | 2022 | |
| Ucb, INC. | $18.28 | 2019 | |
| Alfasigma USA, INC. | $15.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Somal Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.